<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282346</url>
  </required_header>
  <id_info>
    <org_study_id>SLX84</org_study_id>
    <nct_id>NCT01282346</nct_id>
  </id_info>
  <brief_title>SOLX Gold Shunt for Refractory Glaucoma</brief_title>
  <official_title>Clinical Evaluation of the SOLX Gold Shunt for the Reduction of Intraocular Pressure (IOP) in Refractory Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOLX, Inc.</source>
  <brief_summary>
    <textblock>
      To establish the clinical performance of the SOLX Gold Shunt for its ability to reduce
      intraocular pressure (IOP) in eyes with refractory glaucoma where medical and conventional
      surgical treatments have failed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eyes that achieve an IOP of &gt; 5mmHg and ≤ 21 mmHg, irrespective of medication use</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average change in IOP</measure>
    <time_frame>1 &amp; 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in IOP from baseline</measure>
    <time_frame>1 &amp; 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change in number of glaucoma medications</measure>
    <time_frame>1 &amp; 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity changes</measure>
    <time_frame>1 &amp; 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open Angle</condition>
  <arm_group>
    <arm_group_label>SOLX Gold Shunt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SOLX Gold Shunt</intervention_name>
    <description>Single use implant</description>
    <arm_group_label>SOLX Gold Shunt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary open-angle glaucoma

          -  age 21 or over

          -  refractory glaucoma, with IOP ≥ 24 mmHg on medications and failed prior incisional
             glaucoma surgery

          -  detectable visual field defect (negative MD score)

          -  written informed consent

          -  available for up to 24 months follow-up

        Exclusion Criteria:

          -  either eye with VA worse than count fingers

          -  angle closure glaucoma episode within past 12 months

          -  uveitic glaucoma, iridocorneal endothelial (ICE) syndrome, traumatic glaucoma, or
             neovascular glaucoma

          -  diagnosis of pigmentary glaucoma or pseudoexfoliative glaucoma

          -  other significant ocular disease, except cataract

          -  active ocular infection

          -  expected ocular surgery in next 12 months

          -  no suitable quadrant for implant

          -  systemic corticosteroid therapy &gt; 5 mg/day prednisone

          -  intolerance to gonioscopy or other eye exams

          -  mental impairment interfering with consent or compliance

          -  pregnancy

          -  known sensitivity to anticipated medications used at surgery

          -  significant co-morbid disease

          -  concurrent enrollment in another drug or device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilay Shah, MD</last_name>
    <role>Study Director</role>
    <affiliation>The EMMES Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vold Vision, PLLC</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Eye Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Partners of Pennsylvania</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Surgeons</name>
      <address>
        <city>Maryville</city>
        <state>Tennessee</state>
        <zip>37803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottsville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memmen, Ltd</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Campinas</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarity Eye Institute</name>
      <address>
        <city>Vaughan</city>
        <state>Ontario</state>
        <zip>L4K 0C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de l'oeil des Laurentides</name>
      <address>
        <city>Boisbriand</city>
        <state>Quebec</state>
        <zip>J7H 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Ophthalmology Clinic</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1V 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Infrastructure Department and Health Services Fund by the Sheba Medical Center (R.A.)</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Docente La Trinidad</name>
      <address>
        <city>Caracas</city>
        <zip>1080-A</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2011</study_first_posted>
  <disposition_first_submitted>February 20, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 20, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 23, 2017</disposition_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma shunt</keyword>
  <keyword>Ocular implant</keyword>
  <keyword>Gold</keyword>
  <keyword>Trabeculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

